Nama's AI scorecard currently rates Enovis Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ENOV's P/E ratio?

Enovis trades at a trailing price-to-earnings ratio of 7.5.

When does ENOV report earnings?

Enovis's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.04.

What is the ENOV price target?

The median analyst price target from 12 analysts is $36.00, with a range of $24.00 – $47.00.

Is ENOV Shariah compliant?

Nama's AAOIFI-style screen reads Enovis as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Enovis (ENOV)

Healthcare · Medical Devices · NYSE

Enovis (ENOV) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.57B, a trailing price-to-earnings ratio of 7.5 and a free-cash-flow yield of 1.3%. Over the most recent reported fiscal year, revenue grew 6.7%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Hold · 4.8/10

The sections balance. As of Nov 7, 2026.

Momentum

Trailing · -38.0% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-83.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.57B
Trailing P/E	7.5
Price / book	1.1
Price / sales	0.7
FCF yield	1.3%
Dividend yield	—
Gross margin	61.1%
Operating margin	3.1%
Net margin	-48.0%
Revenue growth (YoY)	+6.7%
Revenue growth (3-yr annual)	+12.9%
EPS growth (YoY)	+16.6%
FCF/share growth (YoY)	—
Beta	1.5
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

ENOV earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $1.04). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.88	$0.77	+14.3%	—
Q2 2026	Aug 6, 2026	$0.90	$0.85	+5.9%	$582.78M
Q1 2026	May 7, 2026	$0.89	$0.81	+9.9%	$589.15M
Q4 2025	Feb 26, 2026	$0.95	$0.84	+13.1%	$575.76M

ENOV analyst price target

Median target $36.00 from 12 analysts, ranging $24.00 – $47.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live ENOV data on Nama Insights →

ENOV FAQ

Is ENOV a buy?: Nama's AI scorecard currently rates Enovis Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ENOV's P/E ratio?: Enovis trades at a trailing price-to-earnings ratio of 7.5.
When does ENOV report earnings?: Enovis's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $1.04.
What is the ENOV price target?: The median analyst price target from 12 analysts is $36.00, with a range of $24.00 – $47.00.
Is ENOV Shariah compliant?: Nama's AAOIFI-style screen reads Enovis as Not Shariah Compliant. At least one of the three ratios or the industry test failed.